IOL Chemicals & Pharmaceuticals Ltd. (IOLCP) AI Stock Analysis

• Market Cap: ₹20.02B
• Dividend Yield: 0.97%
• Average Volume (3M): 113.78K
• Price to Earnings (P/E): 29.4
• Beta (1Y): 1.80
• Revenue Growth: 5.74%
• EPS Growth: 16.06%
• Country: IN
• Employees: 2,777
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.10
• Shares Outstanding: 293,527,500
• 10 Day Avg. Volume: 248,884
• 30 Day Avg. Volume: 113,785
• PEG Ratio: -3.72
• Price to Book (P/B): 5.55
• Price to Sales (P/S): 4.53
• P/FCF Ratio: -268.11
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 4.6
• Revenue Forecast (FY): ₹23.14B

• Rating: 60 Neutral
• Price Target: ₹72.00 ▼(-14.38% Downside)
• Action: Reiterated Date: 11/13/25
• Date: Action: Reiterated 11/13/25

The overall stock score of 60 reflects a stable financial position with a strong balance sheet, but challenges in revenue growth and cash flow optimization. Technical indicators suggest a bearish trend, and the valuation indicates moderate pricing with limited dividend income potential. The absence of recent earnings call data or notable corporate events leaves these areas unassessed.

Positive Factors

Strong balance sheet

IOLCP's strong balance sheet, healthy equity ratio and low leverage provide durable financial flexibility. This lowers refinancing risk, supports capital expenditure or expansion into higher‑value APIs, and allows the company to weather cyclical downturns without forcing asset sales or dilutive financing.

Established API & specialty franchise

As an established manufacturer of APIs and specialty chemicals with a prominent ibuprofen franchise, IOLCP benefits from long product cycles, technical know‑how and B2B customer relationships. Scale in a core API reduces unit costs and supports steady export revenue over the medium term.

Margin consistency and EPS growth

Consistent gross and net margins combined with reported EPS growth indicate underlying profitability discipline and operational resilience. Stable margins help sustain cash generation from operations, enabling reinvestment in capacity or R&D and supporting margin recovery even if top‑line growth moderates.

Negative Factors

Declining free cash flow

The decline in free cash flow and weak free‑cash‑flow to net‑income ratio reduce the company’s ability to fund capex organically, pay down debt, or return cash to shareholders. Over months this constrains strategic investments and heightens sensitivity to working‑capital swings and input cost volatility.

Revenue pressure

A recent decline in revenue signals demand weakness or competitive pressure in key API or chemical segments. If sustained, this erodes scale advantages, compresses margins, and requires either market diversification or pricing actions that can be costly and slow to implement, reducing medium‑term growth prospects.

Margin & ROE compression

Decreasing EBIT/EBITDA margins and lower return on equity point to deteriorating operating efficiency or rising input costs. Persisting margin pressure will hamper profitability, reduce retained earnings available for reinvestment, and could necessitate restructuring or pricing changes to restore long‑term shareholder returns.

IOL Chemicals & Pharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

IOL Chemicals and Pharmaceuticals Limited manufactures and sells pharmaceutical and chemical products in India and internationally. The company offers active pharmaceutical ingredients (API), such as ibuprofen, ibuprofen lysinate, ibuprofen sodium, and dex- ibuprofen; and other APIs, including metformin hydrochloride, clopidogrel bisulphate, pantoprazole sodium, ursodeoxycholic acid, losartan potassium, gabapentin, levetiracetam, lamotrigine, and fenofibrate. Its products are used for treatments, which include anti-inflammatory, analgesic and antipyretic, anti-diabetic, anti- platelet, anti-cholesterol, anti- convulsant, anti-cholelithic, as well as proton pump inhibitor. The company also provides specialty industrial chemicals comprising ethyl acetate, iso butyl benzene, acetyl chloride, and mono chloro acetic acid for use in food processing, flexible packaging, pharmaceuticals, textiles, ink, paint, pesticides, and chemical intermediates industries. IOL Chemicals and Pharmaceuticals Limited was incorporated in 1986 and is headquartered in Ludhiana, India.

How the Company Makes Money

IOLCP primarily makes money by manufacturing and selling (1) pharmaceutical APIs—most notably ibuprofen—along with other APIs/intermediates, and (2) specialty/industrial chemicals and chemical intermediates. Revenue is generated through business-to-business sales to pharmaceutical formulators, generic-drug companies, contract manufacturers, and chemical industry customers, both in India and export markets. Earnings are driven by sales volumes and realized prices for APIs/chemicals, the product mix (higher-margin APIs vs. lower-margin commodity-like chemicals), and the spread between selling prices and input costs for key raw materials and utilities. The company’s profitability can be influenced by demand cycles in the ibuprofen/API market, competitive dynamics, capacity utilization, and changes in raw-material and energy prices. Specific details on major customer concentration, named long-term partnerships, or contract structures are not available in the provided context; therefore: null.

IOL Chemicals & Pharmaceuticals Ltd. Financial Statement Overview

Summary

IOL Chemicals & Pharmaceuticals Ltd. presents a stable financial position with a robust balance sheet and prudent leverage. However, challenges are evident in maintaining revenue growth and optimizing cash flow. Continued focus on improving profitability and cash management is essential to support long-term growth.

Income Statement

The company shows modest profitability with a consistent gross profit margin and net profit margin over the years. However, there is a recent decline in revenue, reflecting a potential challenge in sustaining growth. The EBIT and EBITDA margins have also decreased, indicating pressure on operating efficiency.

Balance Sheet

The balance sheet is strong with a healthy equity ratio and low leverage, indicating financial stability. The company's debt-to-equity ratio is favorable, reflecting prudent financial management. However, the return on equity has decreased, suggesting a need for improved profitability to enhance shareholder returns.

Cash Flow

The cash flow analysis indicates a decline in free cash flow, which may affect future investment capabilities. The operating cash flow is positive, but the free cash flow to net income ratio is concerning, suggesting potential inefficiencies in cash management.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	21.70B	20.68B	21.19B	22.02B	21.84B	19.46B
Gross Profit	7.38B	6.54B	2.70B	6.41B	5.72B	8.22B
EBITDA	2.52B	2.25B	2.61B	2.46B	2.71B	6.11B
Net Income	1.16B	1.01B	1.34B	1.39B	1.68B	4.45B
Balance Sheet
Total Assets	24.13B	23.82B	22.44B	20.22B	19.62B	16.10B
Cash, Cash Equivalents and Short-Term Investments	1.79B	2.09B	1.43B	186.40M	1.20B	3.37B
Total Debt	1.59B	1.17B	327.60M	798.10M	439.50M	27.30M
Total Liabilities	6.62B	6.94B	6.33B	5.14B	5.70B	3.50B
Stockholders Equity	17.51B	16.88B	16.12B	15.08B	13.92B	12.60B
Cash Flow
Free Cash Flow	-535.70M	-349.30M	159.10M	-895.50M	-602.40M	2.72B
Operating Cash Flow	110.60M	1.79B	2.90B	1.22B	930.50M	3.80B
Investing Cash Flow	-961.60M	-1.54B	-1.91B	-1.20B	-1.21B	-3.17B
Financing Cash Flow	342.30M	460.40M	-925.00M	-41.10M	-16.40M	-582.80M

IOL Chemicals & Pharmaceuticals Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 84.09
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:IOLCP, the sentiment is Negative. The current price of 84.09 is above the 20-day moving average (MA) of 72.35, above the 50-day MA of 73.93, and below the 200-day MA of 88.48, indicating a bearish trend. The MACD of -1.30 indicates Positive momentum. The RSI at 38.67 is Neutral, neither overbought nor oversold. The STOCH value of 15.86 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:IOLCP.

IOL Chemicals & Pharmaceuticals Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ROSSARI	64 Neutral	₹23.44B	24.59	―	0.09%	15.47%	-1.72%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
IOLCP	60 Neutral	₹20.02B	29.38	―	0.97%	5.74%	16.06%
TATVA	53 Neutral	₹27.23B	51.39	―	0.07%	16.88%	0.69%
PRINCEPIPE	51 Neutral	₹26.41B	-310.89	―	0.20%	-4.37%	-82.37%
FAIRCHEMOR	47 Neutral	₹6.47B	-2,425.33	―	1.07%	-22.10%	-85.56%
TIRUMALCHM	45 Neutral	₹19.75B	-15.05	―	0.43%	-11.11%	-340.74%

IOL Chemicals & Pharmaceuticals Ltd. Corporate Events

IOL Chemicals & Pharmaceuticals Defends Compliance of Q3 FY2025 Financial Results

IOL Chemicals & Pharmaceuticals has clarified to the National Stock Exchange that its standalone and consolidated financial results for the quarter ended 31 December 2025 were prepared in full compliance with Indian Accounting Standards and the format prescribed under Schedule III of the Companies Act. The company addressed concerns that the submitted Q3 figures were not in the correct format and that standalone and consolidated numbers appeared identical.

Management explained that the close similarity in standalone and consolidated figures reflects the fact that, apart from one Section 8 subsidiary, its subsidiaries had not commenced business operations during the reporting period, resulting in only limited differences in profit, depreciation, and other expenses. IOL Chemicals & Pharmaceuticals has requested that the exchange accept and take on record the previously filed Q3 results as valid and compliant, aiming to dispel any doubts over its financial disclosure practices.